No writing assistance was utilized in the production of this manuscript. Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis (JIA ...

Patients with rheumatoid arthritis (RA) achieved a 59.4% success rate with methotrexate (MTX) monotherapy, with remission or low disease activity linked to lower baseline disease activity, normal ...

A new study published in the Journal of the European Academy of Dermatology and Venereology found that methotrexate (MTX) has ...

The following is a summary of “High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis,” published in the October 2024 issue ...

Key: AS = Ankylosing spondylitis; DMARD = disease-modifying antirheumatic drug; ERA = Enthesitis-related arthritis; JPsA = Juvenile psoriatic arthritis; MTX = methotrexate; nr-axSpA = non ...

The researchers noted a clear association between creatinine clearance and AUCHD-MTX, which allowed them to model an equation to predict clearance of methotrexate that was not affected by patient ...

Methotrexate sodium 2.5mg; scored tabs. Be fully familiar with this drug's toxicity before use. Obtain baseline and monitor CBCs for myelosuppression, and hepatic, renal and pulmonary function ...

Methotrexate (MTX), an older oral DMARD, remains the gold standard of treatment and is included in most combination therapy strategies. However, traditional DMARDs have a slow onset of action and ...

will share ex vivo data demonstrating the efficacy of DC-9476 in cells from RA patients that have had an inadequate response to methotrexate (MTX-IR). RA affects approximately 1% of the population ...

Treatment with methotrexate (MTX) (20 mg s.c. weekly) and prednisolone (most recently, 5 mg p.o. daily) had been ongoing since the initial RA diagnosis 17 years previously. There were no clinical ...